-
SM-102 Workflow for mRNA Delivery
2026-09-19
Build a more reproducible mRNA delivery workflow around SM-102 by controlling solvent handling, rapid lipid–RNA mixing, physicochemical quality control, and cell-based validation. The article also contrasts SM-102 lipid nanoparticles with a polyphenol–polypeptide platform that offers pH-responsive nucleic acid release.
-
Sequencing Therapy in Waldenström Macroglobulinemia
2026-09-18
The 2021 reference paper reframes Waldenström macroglobulinemia treatment selection as a genotype- and patient-informed sequencing problem rather than a fixed regimen hierarchy. Its central practical contribution is linking MYD88 and CXCR4 status with expected treatment response, while emphasizing clinical presentation, comorbidities, toxicity, patient preference, and clinical-trial access.
-
Bazedoxifene Blocks Malaria Growth and Hemozoin Formation
2026-09-18
The reference study identifies bazedoxifene, a third-generation selective estrogen receptor modulator, as an inhibitor of blood-stage Plasmodium growth and hemozoin formation. Its stage-selective activity, effects in drug-resistant parasites, and sex-dependent response in mice support drug repurposing while also defining important limits for translation.
-
2-Thio-dCTP for Precision DNA Assays
2026-09-17
2-Thio-dCTP enables controlled sulfur substitution in DNA for polymerase selectivity, site-specific DNA modification, and DNA–protein interaction studies. This practical guide also explains how to keep nucleotide chemistry separate from the SCP4–H3T3 chromosome-stability pathway while using orthogonal assays to strengthen mechanistic conclusions.
-
Toremifene Citrate: An Assay-First Research Guide
2026-09-17
Toremifene Citrate is an oral selective estrogen receptor modulator with distinct value in estrogen receptor signaling and breast cancer research. This assay-first guide connects receptor pharmacology, comparative evidence, concentration selection, and translational interpretation without conflating laboratory potency with clinical efficacy.
-
Vasopressin and Its Analogues: Mechanisms and Translation
2026-09-16
The reference review explains how vasopressin structure, receptor selectivity, metabolic stability, and route of administration shape the behavior of natural and synthetic analogues. Its main practical contribution is a framework for connecting peptide chemistry with antidiuretic therapy, vasoconstriction research, receptor assays, and cautiously interpreted antiviral hypotheses.
-
Beyond Membrane Disruption: Translational Lessons from YZ462
2026-09-16
YZ462 illustrates how membrane disruption, permeability changes, endogenous ROS, and biofilm activity can inform a more disciplined antimicrobial development strategy. This article translates those findings into experimental decision points while positioning Recombinant Human IL-12 as a carefully controlled exploratory variable for host-context studies.
-
PD0325901 as a MEK Probe in Cell-State Assays
2026-09-15
PD0325901 is a selective MEK inhibitor for dissecting RAS/RAF/MEK/ERK signaling alongside differentiation and protein-secretion assays. This article shows how to pair pathway readouts with O-GlcNAc and galectin-3 measurements for more informative cell-state interpretation.
-
PDHA1 Succinylation Rewires Cholangiocarcinoma Immunity
2026-09-15
The reference study identifies PDHA1 lysine 83 succinylation as a metabolic-to-immune switch in cholangiocarcinoma. By increasing PDH activity and promoting α-ketoglutarate accumulation, this modification activates macrophage OXGR1–MAPK signaling, suppresses MHC-II antigen presentation, and may contribute to chemotherapy resistance.
-
BteA, Akt/mTOR, and Bordetella Persistence
2026-09-14
The reference study identifies a previously underappreciated Bordetella strategy in which the T3SS effector BteA activates host Akt/mTOR signaling in epithelial cells and eosinophils to increase IL-1Ra expression. Genetic or antibody-mediated loss of IL-1Ra accelerated bacterial clearance in vivo, connecting eosinophil–epithelial communication with immune evasion and persistent respiratory infection.
-
Tamoxifen: Mechanisms, Evidence, and Research Use
2026-09-14
Tamoxifen is a selective estrogen receptor modulator with antagonist activity in breast tissue and agonist activity in selected other tissues. Its research value spans breast cancer research, CreER-mediated gene knockout, and cell-signaling studies, but dose-, tissue-, and exposure-specific effects require careful controls.
-
Cholecystokinin octapeptide ammonium: LTP Workflow
2026-09-13
Cholecystokinin octapeptide ammonium enables receptor-resolved studies of hippocampal plasticity, opioid-related memory impairment, neuronal survival, and broader brain–gut signaling. This workflow translates the CCK-2 receptor finding from a rat LTP model into practical assay design, handling controls, and troubleshooting decisions.
-
PRMT5, Splicing, and Glutamine Metabolism in Neuroblastoma
2026-09-12
This Cancer Letters study shows that MYCN-amplified neuroblastoma is unusually dependent on PRMT5-regulated RNA splicing, with downstream effects on epitranscriptomic control and glutamine metabolism. Its integrated genetic, transcriptomic, metabolic, and in vivo data identify GLS regulation as a mechanistic consequence of PRMT5 inhibition and provide a rationale for testing downstream glutaminolysis interventions.
-
Inducing Embryonic Dormancy Through mTOR Inhibition
2026-09-11
This Nature Protocols article presents noninvasive in vitro procedures for placing mouse blastocysts, human blastoids, and pluripotent stem cells into a reversible diapause-like state through pharmacological mTOR inhibition. The workflow replaces laborious surgery-based models with scalable culture systems for studying dormancy, developmental competence, and the molecular control of early embryogenesis.
-
MRSA Extracellular Vesicles Drive OSCC via IL-8
2026-09-11
This study identifies methicillin-resistant Staphylococcus aureus extracellular vesicles as active drivers of oral squamous cell carcinoma progression, rather than passive markers of infection. By combining EV comparisons, pathway inhibition, IL-8 loss-of-function, and CXCR1 blockade, the work connects bacterial resistance biology to an ERK/c-Jun–IL-8–CXCR1–JAK/STAT5A proliferative circuit.